Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

证券日报网讯1月5日，东方海洋（002086）在互动平台回答投资者提问时表示，公司股东人数请关注公 司定期报告，公司发布的《2025年三季度报告》披露截至2025年9月30日股东总数为72503户。 ...

Core Viewpoint - The second extraordinary general meeting of shareholders for Shandong Oriental Ocean Technology Co., Ltd. was held, where the proposal to elect Mr. Zhang Zhonghua as an independent director was not approved [1]. Meeting Details - The meeting was scheduled for December 26, 2025, at 9:30 AM [2]. - Voting was conducted both on-site and online, with specific time slots for each method [3]. - The meeting took place at the company's conference room located at 18 Aokema Street, Laishan District, Yantai City, Shandong Province [4]. Attendance and Voting - A total of 694 shareholders attended the meeting, representing 790,662,289 shares, which is 40.3616% of the total voting shares [7]. - Among them, 2 shareholders attended in person, representing 67,200,120 shares (3.4304%), while 692 participated via online voting, representing 723,462,169 shares (36.9312%) [7]. - For minority shareholders, 692 attended, representing 299,561,099 shares (15.2919%) [9]. Voting Results - The proposal to elect Mr. Zhang Zhonghua as an independent director was not passed, with 268,053,141 shares in favor (33.9024%), 363,107,163 shares against (45.9244%), and 159,501,985 shares abstaining (20.1732%) [10]. - Among minority shareholders, 89.4820% voted in favor, while 1.8182% opposed, and 8.6998% abstained [11]. Legal Compliance - The meeting's convening and procedures were confirmed to comply with relevant laws and regulations, as stated in the legal opinion provided by Shandong Xintong Law Firm [13].

山东鑫同律师事务所 关于山东东方海洋科技股份有限公司 2025年第二次临时股东会的 法律意见书 地址：山东省烟台市芝罘区万达金融中心B座11楼 电话：0535-6213036 邮编：264000 山东鑫同律师事务所 法律意见书 本所声明：本所律师仅对本次股东会的召集程序、召开程序、出 席会议人员资格、召集人资格、表决程序及表决结果发表法律意见， 并不对本次股东会所审议的议案、议案所涉及的数字及内容发表意见。 本所律师同意将本法律意见书随本次股东会其他信息披露资料一并 公告。 本法律意见书仅供见证公司本次股东会相关事项的合法性之目 的使用，不得用作任何其他目的。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定 及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法 1 山东鑫同律师事务所 法律意见书 山东鑫同律师事务所 关于山东东方海洋科技股份有限公司 2025 年第二次临时股东会的法律意见书 致：山东东方海洋科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"） ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-072 山东东方海洋科技股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东会审议的议案《关于选举张中华先生为公司第八届董事会独立董事 的议案》未表决通过； 2．本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间： （1）现场会议的召开时间为：2025 年 12 月 26 日（星期五）上午 9:30。 （2）网络投票时间：2025 年 12 月 26 日，其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 12 月 26 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网系统进行网络投票的具体时间为 2025 年 12 月 26 日 9:15-15:00 的任意时间。 2．现场会议地点：山东省烟台市莱山区澳柯玛大街18号公司会议室。 3．会议召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 4 ...

山东东方海洋科技股份有限公司关于持股5%以上股东权益变动后持股比例触及1%及5%整数倍的提示性 公告 国元基金保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 深圳前海国元私募证券基金管理有限公司－国元价值精选一号私募证券投资基金（以下简称"国元基 金"）为持有山东东方海洋科技股份有限公司（以下简称"公司"）5%以上股份的大股东。公司于2025年 8月12日披露了《关于持股5%以上股东权益变动后持股比例触及1%及5%整数倍的提示性公告》（公告 编号：2025-040），国元基金于2025年6月5日至2025年8月11日以集中竞价方式减持公司股份15,865,000 股，持股比例变更为10.00%，权益变动后的持股比例触及1%及5%的整数倍。 公司于2025年8月19日披露了《关于持股5%以上股东减持股份实施情况的公告》（公告编号：2025- 041），国元基金于2025年8月18日以集中竞价方式减持公司股份3,715,000股，持股比例变更为9.81%。 公司于2025年9月18日披露了《关于持股5%以上股东减 ...

山东东方海洋科技股份有限公司 简式权益变动报告书 签署日期: 二〇二五年十二月 上市公司:山东东方海洋科技股份有限公司 上市地点:深圳证券交易所 股票简称:东方海洋 股票代码: 002086.SZ 信息披露义务人:深圳前海国元私募证券基金管理有限公司(代表国元价 值精选一号私募证券投资基金) 住所/通讯地址:深圳市前海深港合作区前湾一路 1 号 A 栋 201 室 ( 入驻 深圳市前海商务秘书有限公司) 股份变动性质:股份减少 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系信息披露义务人依据《证券法》《收购办法》和《淮则15 号》等法律、法规及规范性文件编制。 二、依据《证券法》《收购办法》和《准则 15 号》等法律法规的规定,本 报告书已全面披露信息披露义务人在山东东方海洋科技股份有限公司拥有权益 的股份;截至本报告书签署之日,除本报告书披露的持股信息外,上述信息披露 义务人没有通过任何其他方式在山东东方海洋科技股份有限公司拥有权益。 三、信息披露义务人签署本报告书已获得必要的授权和批准,其履行亦不违 反信息披露义务人的公司章程或内部规则中的任何条款, ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-071 山东东方海洋科技股份有限公司 关于持股 5%以上股东权益变动后持股比例触及 1%及 5% 整数倍的提示性公告 1 号：2025-061），国元基金于 2025 年 9 月 23 日通过大宗交易方式减持公司股份 19,481,000 股，于 2025 年 11 月 10 日通过集中竞价方式减持公司股份 99,000 股， 共计减持 19,580,000 股，持股比例由 8.00%变更为 7.00%，变动触及 1%的整数 倍。公司于 2025 年 11 月 18 日披露了《关于持股 5%以上股东减持股份实施情况 的公告》（公告编号：2025-062），国元基金于 2025 年 11 月 17 日以集中竞价 方式减持公司股份 3,715,000 股，持股比例变更为 6.81%。公司于 2025 年 12 月 24 日披露了《关于持股 5%以上股东减持股份触及 1%整数倍的公告》（公告编 号：2025-069），国元基金于 2025 年 12 月 19 日至 2025 年 12 月 22 日通过集中 竞价方式减持公司股份 15,385,000 股 ...

Core Viewpoint - The announcement indicates that Shenzhen Qianhai Guoyuan Private Securities Fund Management Co., Ltd. has reduced its stake in Dongfang Ocean by selling 97.9 million shares, representing 5.00% of the company's total share capital, with the possibility of further reductions in the next 12 months [1] Group 1 - The fund's shareholding decreased from 10.00% to 5.00% after the reduction [1] - The shares were sold at a price range of 2.12 to 2.99 yuan per share [1] - The total amount from the reduction through centralized bidding was approximately 104.23 million yuan, while the amount from block trading was about 148.35 million yuan [1]

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]